giovedì, Dicembre 12, 2024

Gli effetti del caffè sul microbiota non sono casuali: eccovi Lawsonibacter e come lavora per farci stare in salute

Diversi studi hanno riportato che l'assunzione di caffè può...

Intelligenza artificale integrata alla mammografia: per la vera diagnosi di precisione del futuro

Un nuovo studio della Washington University School of Medicine...

SAMTOR: il sensore della metionina da sfruttare nella terapia oncologica mirata

Il complesso mTOR (mTORC1) regola la crescita cellulare e...

Autoimmunities after infertility? A representative population with its prevalence, risks and possible mechanisms

Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a naturally conceived birth compared to women without fertility problems. The new research, published in the specialized journal Human Reproduction, indicates that this was true even after accounting for higher rates of pre-eclampsia (high blood pressure during pregnancy), preterm birth (babies born alive earlier than 37 weeks) and stillbirth, all of which are associated with infertility and its treatments. The researchers from the University of Toronto Scarborough, Canada, say their findings should alert doctors to the possibility that women with infertility may be at risk of future SARD or may have undiagnosed and untreated SARD. SARD are rare but debilitating conditions in which the immune system becomes overactive and attacks the body’s own tissues. SARD include systemic sclerosis, systemic lupus erythematosus, Sjögren’s syndrome and inflammatory myopathy.

SARDs affects women more than men, and usually during their reproductive years. While previous research has shown that women with infertility often have unusual immune system activity, there was little research on how infertility might be linked to autoimmune diseases. The researchers analysed data on 568,053 singleton births between 2012 and 2021 among 465,078 women aged 18 to 50 years without known pre-existing SARD. The researchers looked at women with no infertility who conceived naturally (88% of the group) and used them as the reference group against which to measure outcomes for three further groups: women with infertility who did not have fertility treatment (9.2% of the group); women with infertility who had non-invasive fertility treatment such as ovulation induction or intrauterine insemination (1.4%); and women with infertility who had invasive fertility treatment such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI), 1.4% of the group.

The researchers adjusted their analyses to take account of factors that could affect outcomes, such as age at delivery, pre-existing conditions such as diabetes, obesity and endometriosis, maternal smoking, and reproductive history, including pre-eclampsia, previous births and stillbirths. They followed the women for an average (median) of 6.5 years, with a range of four to nine years. Scientists found that women who experienced infertility but didn’t use fertility treatments were 25% more likely to develop SARD up to nine years following childbirth. This increased risk persisted even after they accounted for other immune-related pregnancy complications these women might have faced. To put this in perspective, for every 10,000 women followed for a year, they saw about nine new cases of SARD in women without infertility and 13 new cases in women with infertility who did not use fertility treatments. Interestingly, women who used fertility treatments, whether non-invasive or more invasive procedures, didn’t show this increased risk.

They had similar rates of autoimmune diseases as women without infertility issues, about 11 new cases of SARD for every 10,000 women followed for a year. Women who receive fertility treatments may come from more privileged backgrounds and may be healthier overall than those without access to these treatments, which puts them at generally lower risk of SARD. These findings are important because they suggest infertility may be an important risk marker for SARD in women who give birth. Mechanisms beneath this correlation have been proposed. Ovulatory dysfunction and ovarian depletion are frequent causes of infertility and potentially share pathophysiological mechanisms with infertility and SARD. Sexual dysfunctions are additional possible mechanisms linking infertility and SARD. Endometriosis, antiphospholipid syndrome and age-related ovarian depletion are additional causes of infertility that could overlap with SARD.

Endometriosis is an inflammatory disease accompanied by immune system dysregulation, which is thought to explain why endometriosis is frequently comorbid with SARD and other autoimmune diseases and why some experts believe that endometriosis may be an autoimmune disease itself. Given ots overal prevalence, it is altogether possible that endometriosis is a predisposing condition for women to develop a SARD. These conditions can be tricky to diagnose, often taking years of untreated symptoms and multiple health care visits before a proper diagnosis is made. Early detection is crucial for preventing organ damage, improving treatment outcomes, and helping patients maintain the best quality of life possible.

  • Edited by Dr. Gianfrancesco Cormaci, PhD; specialist in Clinical Biochemistry.

Scientific references

Scime N et al. Human Reprod. 2024 Dec; deae253.

Scime NV et al. BMC Public Health. 2024; 24(1):3112.

Banack HR et al. Hum Reprod. 2024; 39(8):1804-15.

Scime NV et al. Hum Reprod. 2023; 38(9):1843-52.

Latest

Intelligenza artificale integrata alla mammografia: per la vera diagnosi di precisione del futuro

Un nuovo studio della Washington University School of Medicine...

SAMTOR: il sensore della metionina da sfruttare nella terapia oncologica mirata

Il complesso mTOR (mTORC1) regola la crescita cellulare e...

Newsletter

Don't miss

Intelligenza artificale integrata alla mammografia: per la vera diagnosi di precisione del futuro

Un nuovo studio della Washington University School of Medicine...

SAMTOR: il sensore della metionina da sfruttare nella terapia oncologica mirata

Il complesso mTOR (mTORC1) regola la crescita cellulare e...

Filgotinib per il trattamento della malattia di Crohn: i risultati di un ultimo trial clinico di fase 3

Il morbo di Crohn è caratterizzato da un'infiammazione transmurale...
Dott. Gianfrancesco Cormaci
Dott. Gianfrancesco Cormaci
Laurea in Medicina e Chirurgia nel 1998; specialista in Biochimica Clinica dal 2002; dottorato in Neurobiologia nel 2006; Ex-ricercatore, ha trascorso 5 anni negli USA (2004-2008) alle dipendenze dell' NIH/NIDA e poi della Johns Hopkins University. Guardia medica presso la casa di Cura Sant'Agata a Catania. Medico penitenziario presso CC.SR. Cavadonna (SR) Si occupa di Medicina Preventiva personalizzata e intolleranze alimentari. Detentore di un brevetto per la fabbricazione di sfarinati gluten-free a partire da regolare farina di grano. Responsabile della sezione R&D della CoFood s.r.l. per la ricerca e sviluppo di nuovi prodotti alimentari, inclusi quelli a fini medici speciali.

Parkinson: il carburante delle cellule malate si chiama NAR

La vitamina B3 o nicotinammide può aiutare a fermare la morte delle cellule nervose che si verifica nella malattia di Parkinson, secondo un recente...

Artrite reumatoide: cercando le connessioni fra salute mentale e ricadute

Alcune ricerche del Dipartimento di Biologia Infiammatoria, Scuola di Immunologia e Microbiologia del King’s College di Londra, ha dimostrato che esiste un aumento del...

Proteasome anchors to neuronal membranes to become a signaling platform: moonlightner or hidden deceiver?

Within the nervous system, the proteasome system (PROS) has been reported to be involved in a number of cellular processes. Furthermore, PROS appears to...

Questo si chiuderà in 20 secondi